Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Herpesviridae Infections 1HIV Infections 1Epstein-Barr Virus Infections 1Cytomegalovirus Infections 1Acquired Immunodeficiency Syndrome 1AIDS-Related Opportunistic Infections 1

Interventions

Doxorubicin 13Zidovudine 12Vincristine 11Bleomycin 8Cyclophosphamide 7Interferon alpha-2 6Etoposide 5Dexamethasone 5sargramostim 4Specimen Handling 4Methotrexate 4Magnetic Resonance Spectroscopy 4Leucovorin 4Filgrastim 4Cytarabine 4Rituximab 3Prednisone 3Nivolumab 3interferon alfa-n1 2cabozantinib 2Thalidomide 2Isotretinoin 2Interleukin-2 2Fluorouracil 2Didanosine 2Bortezomib 2Biopsy 2Allopurinol 2prednylidene 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × HIV Infections × Acyclovir × Clear all
NCT00000712 2021-11-04

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
400 enrolled

Acquired Immunodeficiency Syndrome, Cytomegalovirus Infections, Herpesviridae Infections, HIV Infections, AIDS-Related Opportunistic Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡